A new study uncovers novel copy number signatures in ovarian cancer genomes. This work sheds light on mutational processes driving ovarian cancer, reveals the distribution of copy number features across the patient population and identifies new genomic properties related to treatment response.
This is a preview of subscription content, log in via an institution to check access.
References
Cancer Genome Atlas Research Network. Nature 474, 609–615 (2011).
McIntyre, G. et al. Nat. Genet. https://doi.org/10.1038/s41588-018-0179-8 (2018).
Patch, A.-M. et al. Nature 521, 489–494 (2015).
McPherson, A. et al. Nat. Genet. 48, 758–767 (2016).
Wang, Y. K. et al. Nat. Genet. 49, 856–865 (2017).
Davies, H. et al. Nat. Med. 23, 517–525 (2017).
Alexandrov, L. B. et al. Nature 500, 415–421 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing Interests
S.P.S. is a principal shareholder of Contextual Genomics, Inc.
Rights and permissions
About this article
Cite this article
Shah, S.P. Copy number signatures in ovarian cancer. Nat Genet 50, 1208–1209 (2018). https://doi.org/10.1038/s41588-018-0212-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-018-0212-y
- Springer Nature America, Inc.
This article is cited by
-
Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability
Chromosome Research (2023)
-
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Nature Reviews Cancer (2022)